Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00316
|
|||||
| Drug Name |
Oxaliplatin
|
|||||
| Synonyms |
ACT 078; Oxaloplatine; Oxaloplatino; Oxalitin; NSC 271670; Oxalato(1,2-diaminocyclohexane)platinum(II); Platinum (II), (cyclohexane-1,2-diammine)oxalato-; CCRIS 9143; Platinum, (1,2-cyclohexanediamine-N,N')(ethanedioato(2-)-O,O')-, (SP-4-2-(trans))-; Platinum, (1,2-cyclohexanediamine-kappaN,kappaN')(ethanedioato(2-)-kappaO1,kappaO2)-, (SP-4-2-(trans))-; Oxaliplatin [USAN:USP:INN:BAN]; CS-0992; HY-17371; NCI60_002138
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Colorectal cancer [ICD11:2B91] | Approved | [1] | |||
| Therapeutic Class |
Anticancer Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C8H12N2O4Pt
|
|||||
| Canonical SMILES |
C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)[O-])[O-].[Pt+4]
|
|||||
| InChI |
InChI=1S/C6H12N2.C2H2O4.Pt/c7-5-3-1-2-4-6(5)8;3-1(4)2(5)6;/h5-8H,1-4H2;(H,3,4)(H,5,6);/q-2;;+4/p-2/t5-,6-;;/m1../s1
|
|||||
| InChIKey |
DWAFYCQODLXJNR-BNTLRKBRSA-L
|
|||||
| CAS Number |
CAS 61825-94-3
|
|||||
| Pharmaceutical Properties | Molecular Weight | 395.28 | Topological Polar Surface Area | 82.3 | ||
| Heavy Atom Count | 15 | Rotatable Bond Count | 0 | |||
| Hydrogen Bond Donor Count | 2 | Hydrogen Bond Acceptor Count | 6 | |||
| PubChem CID | ||||||
| PubChem SID |
125309438
,127301221
,127301222
,127301223
,127301224
,127301225
,127301226
,127301227
,127301228
,127301229
,127301230
,127301231
,127301232
,127301233
,127301234
,127301235
,127301236
,127301237
,127301238
,127301239
,127301240
,127301241
,127301242
,127301243
,127301244
,127301245
,127301246
,135684119
,137001870
,14854529
,14903423
,152059544
,162036207
,164196639
,174477519
,226396770
,24173438
,251885690
,252156659
,252316548
,45633994
,57373686
,7848852
,78790585
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | 1-Oct | Transporter Info | Organic cation transporter 1 | Substrate | [2] | |
| 2-Oct | Transporter Info | Organic cation transporter 2 | Substrate | [3] | ||
| ABCG1 | Transporter Info | ATP-binding cassette sub-family G member 1 | Substrate | [4] | ||
| BCRP | Transporter Info | Breast cancer resistance protein | Substrate | [5] | ||
| CTR1 | Transporter Info | High affinity copper uptake protein 1 | Substrate | [6] | ||
| MRP2 | Transporter Info | Multidrug resistance-associated protein 2 | Substrate | [7] | ||
| References | ||||||
| 1 | Oxaliplatin was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res. 2006 Sep 1;66(17):8847-57. | |||||
| 3 | Relevance of copper transporter 1 and organic cation transporters 1-3 for oxaliplatin uptake and drug resistance in colorectal cancer cells. Metallomics. 2018 Mar 1;10(3):414-425. | |||||
| 4 | The role of ATP-binding cassette subfamily G member 1 in tumor progression. Cancer Med. 2024 Jun;13(12):e7285. | |||||
| 5 | Effect of ABCG2 on cytotoxicity of platinum drugs: interference of EGFP. Toxicol In Vitro. 2008 Dec;22(8):1846-52. | |||||
| 6 | Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs. Crit Rev Oncol Hematol. 2005 Jan;53(1):13-23. | |||||
| 7 | Multidrug Resistance-Associated Protein 2 (MRP2) Mediated Transport of Oxaliplatin-Derived Platinum in Membrane Vesicles. PLoS One. 2015 Jul 1;10(7):e0130727. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.